Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061538 | 0.89 | SMN1; SMN2 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL1061957 | 0.88 | SMN1; SMN2 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL12962917 | 0.81 | NPC1 (0.45) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1063432 | 0.80 | SMN1; SMN2 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1061747 | 0.78 | SMN1; SMN2 (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL13708842 | 0.78 | KDM4E (0.47) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL1062395 | 0.77 | KDM4E (0.51) | MEN1KMT2ANPC1ALDH1A1KDM4E | |
| SCHEMBL1062301 | 0.76 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1062189 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1057564 | 0.73 | SMN1; SMN2 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | MEN1 2094/4885KMT2A 386/4885NPC1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.